Pfizer News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

26.12.22	Accelleron-Aktie, Porsche-Aktie & Co.: Das wurde aus den 2022er IPOs (finanzen.ch) Regelmässig wird die Börsenlandschaft durch weitere Unternehmen ergänzt - so auch 2022. Diese Neuankömmlinge standen dabei besonders im Fokus der Anleger.» mehr
21.12.22	Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis (Businesswire)
20.12.22	Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts (Businesswire)
10.12.22	Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial (Businesswire)
09.12.22	Pfizer Declares First-Quarter 2023 Dividend (Businesswire)
09.12.22	Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza (RSS)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (Businesswire)
08.12.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
07.12.22	U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults (Businesswire)
06.12.22	Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease (Businesswire)
05.12.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years (RSS)
01.12.22	Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day (Businesswire)
18.11.22	Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages (RSS)
17.11.22	Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection (RSS)
16.11.22	Form 4 78003 (RSS)
11.11.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
10.11.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union (RSS)
09.11.22	Form 10-Q 78003 (RSS)
04.11.22	Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine (RSS)
03.11.22	Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma (Businesswire)
03.11.22	Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19 (RSS)
01.11.22	PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK (Businesswire)
01.11.22	Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate (Businesswire)
01.11.22	Form 8-K 78003 (RSS)
19.10.22	Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union (RSS)
18.10.22	Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022 (Businesswire)
13.10.22	Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older (RSS)
13.10.22	Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older (Businesswire)
12.10.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
12.10.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
07.10.22	Pfizer and BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older (RSS)
05.10.22	Pfizer Completes Acquisition of Global Blood Therapeutics (Businesswire)
04.10.22	Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial (Businesswire)
03.10.22	Pfizer Completes Acquisition of Biohaven Pharmaceuticals (Businesswire)
28.09.22	Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
26.09.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (RSS)
26.09.22	Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age (Businesswire)
22.09.22	Pfizer Declares Fourth-Quarter 2022 Dividend (Businesswire)
22.09.22	Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries (Businesswire)
20.09.22	Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts (Businesswire)
19.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union (Businesswire)
16.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union (RSS)
15.09.22	Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents (Businesswire)
14.09.22	Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 (Businesswire)
14.09.22	Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine (Businesswire)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (RSS)
12.09.22	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union (Businesswire)
09.09.22	FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata (Businesswire)
07.09.22	FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women (Businesswire)
06.09.22	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	81.32	2.01 %	K V
Alcon	79.46	1.90 %	K V
Sonova Hldg	308.90	1.55 %	K V
ABB	51.64	1.29 %	K V
Lonza Grp	570.20	1.24 %	K V
Kuehne+Nagel Int	206.80	0.05 %	K V
Givaudan	3’960.00	-0.08 %	K V
Sika	227.00	-0.09 %	K V
Geberit	505.40	-0.20 %	K V
UBS Group	31.54	-0.66 %	K V